OSP News

Recall of Multiple Drugs Manufactured by Akorn Pharmaceuticals

Posted: 07/06/2023

On June 1, 2023, Akorn Pharmaceuticals initiated a voluntary recall of various products as a result of bankruptcy and discontinuation of quality assurance activities of these marketed products.

The discontinuation of the quality assurance program means the company is not able to support or guarantee that the products meet all intended specifications.

A full list of impacted drugs can be found on the FDA Enforcement Report at fda.gov.

Click here to the read the full article on the Priority Health website.

We value your privacy. We use cookies and other technologies to keep the web site reliable and secure, tailor your experience, and measure web site performance, as described in our Privacy Policy.

x

OSP Technical Support